Tarik Duzenli

Dr. Tarik Duzenli

Medical Genetics, Gazi University, Ankara, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
TDTarik Duzenli
Tarik Duzenli
ASAbdullah Sezer
Abdullah Sezer
GKGulsum Kayhan
Gulsum Kayhan
AAAyse Tana Arslan
Ayse Tana Arslan
FPFerda E. Percin
Ferda E. Percin


24 July 2024 in Ophthalmic Genetics
Verified
Journal Article
Closed access
TDTarik Duzenli
Tarik Duzenli
BUBetul Seher Uysal
Betul Seher Uysal
BUBerkay Ulas
Berkay Ulas
GKGulsum Kayhan
Gulsum Kayhan
Geleophysic dysplasia (GD) and Weill-Marchesani syndrome (WMS) are two rare genetic disorders that are classified as acromelic dysplasias and have many common features that overlap clinically and genetically in some patients. Both diseases are characterized by acromelic features, including short stature, brachydactyly, joint limitations, and cardiac involvement. WMS is distinguished from GD mainly by ocular abnormalities, including high myopia, microspherophakia, ectopia lentis, and glaucoma and the absence of the life-threatening airway stenosis and early lethality. These two syndromes are allelic diseases of the FBN1 gene, with the gene families including A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) and latent transforming growth factor-beta-binding protein (LTBP). Although the ADAMTSL2 gene has been associated only with GD within the acromelic dysplasias, there have been reports of patients with ADAMTSL2-related GD exhibiting ocular abnormalities that resemble WMS. We present a 24-year-old female patient with microspherophakia, ectopia lentis, myopia, short stature, joint stiffness, thick skin, short hands and feet, and cardiac valve disease consistent with WMS. The virtual panel analysis, including WMS and GD-related genes, revealed a homozygous c.493 G>A (p.Ala165Thr) variant in the ADAMTSL2 gene (NM_014694.4), which has been previously reported in a geleophysic dysplasia patient. Mounting evidence suggests that GD and WMS may be allelic diseases of the ADAMTSL2 gene.

11 August 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
KMKenan Moral
Kenan Moral
GKGulsum Kayhan
Gulsum Kayhan
TDTarik Duzenli
Tarik Duzenli
SSSinan Sari
Sinan Sari
MCMehmet Cindoruk
Mehmet Cindoruk
NENergiz Ekmen
Nergiz Ekmen
Background: The etiology of liver disease remains unidentified in approximately 30% of patients, presenting a persistent diagnostic challenge. While whole-exome sequencing (WES) is well established for identifying rare genetic conditions in pediatric populations, its utility in adult hepatology is less defined. This study aimed to evaluate the diagnostic value of WES in adults with unexplained liver disorder. Methods: Fifty-three Turkish adult patients with idiopathic liver disease underwent a comprehensive clinical evaluation and WES at Gazi University Ankara in 2024–2025. The cohort included individuals with idiopathic cholestasis (6/53, 11%), hepatic steatosis (28/53, 53%), unexplained elevated liver enzymes (12/53, 23%), and cryptogenic cirrhosis (7/53, 13%). All patients had inconclusive results from prior standard investigations. Results: ES yielded a definitive molecular diagnosis in 11% (6/53) of cases. Definitive diagnoses were distributed across the following disease categories: idiopathic cholestasis (n = 1), hepatic steatosis (n = 1), elevated liver enzymes (n = 2), and cryptogenic cirrhosis (n = 2). Pathogenic variants were detected in the ABCB4, AGL, APOB, CP, and MTTP genes. One patient was identified with mosaic Turner syndrome. Conclusions: This study highlights the role of rare genetic variants in the etiology of unexplained liver disease in adults. Integrating whole-exome sequencing into hepatology practice can uncover novel disease mechanisms and improve diagnostic yield, informing more precise patient care.

29 April 2025 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
ABAli Babazade
Ali Babazade
TDTarik Duzenli
Tarik Duzenli
SMSerdar Mermer
Serdar Mermer
GKGulsum Kayhan
Gulsum Kayhan

10 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
TDTarik Duzenli
Tarik Duzenli
ABAli Babazade
Ali Babazade
OVOzan Vural
Ozan Vural
YBYusuf Bahap
Yusuf Bahap
MEMehmet Ali Ergün
Mehmet Ali Ergün
Background: The ClinGen ENIGMA BRCA1 / BRCA2 Variant Curation Expert Panel (VCEP) has adapted the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) framework into gene-specific specifications. However, applying these specifications manually remains labor-intensive and prone to inconsistency, requiring integration of population, computational, functional, and clinical evidence through gene-specific decision trees and a points-based classification system. Methods: We developed HECTOR (HEreditary Cancer varianT Online Reclassifier), a free web-based tool that implements the complete ENIGMA VCEP v1.2 specifications for BRCA1 and BRCA2 . HECTOR automatically populates all evidence codes derivable from public data, routes curator-dependent evidence to a manual input layer and returns a transparent five-tier classification with code-level evidence. We validated HECTOR against two independent reference datasets: the 143-variant ENIGMA Evidence Repository, used as a clinical-grade reference standard, and 134 manually curated in-house variants of uncertain significance (132 unique variants). HECTOR was then applied to the complete ClinVar BRCA1 / BRCA2 catalog (n = 34,077). Results: At the criterion level, HECTOR exactly reproduced 326 of 413 VCEP-assigned criteria (78.9%), with discordance arising predominantly from curator-dependent evidence rather than implementation errors. In an independent cohort of 134 manually curated in-house variants, HECTOR was fully concordant with expert consensus at the classification level and, even without auto-populated likelihood-ratio evidence, resolved more variants to a definitive classification than two generic ACMG/AMP classifiers. Across ClinVar, HECTOR classified 33,913 variants. Agreement with definitive ClinVar classifications was 96.7% for pathogenic variants and %72.7 for benign variants overall. Among variants for which HECTOR generated a definitive classification, directional concordance reached 99.7% for pathogenic and 99.9% for benign variants. HECTOR also resolved a substantial proportion of variants classified as uncertain (67.3%) or conflicting (88.7%), predominantly toward benign classifications. Conclusions: HECTOR provides a faithful, transparent implementation of the ENIGMA VCEP v1.2 specifications for BRCA1 and BRCA2 , enabling rapid, standardized, and reproducible application of gene-specific variant classification guidelines while reducing the burden of manual curation.